BioXcel Therapeutics, Inc.

780 East Main Street

Branford, CT 06405

 

March 5, 2018

 

VIA EDGAR

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention:                                         Suzanne Hayes

Mary Beth Breslin

Ada D. Sarmento

 

Re:                             BioXcel Therapeutics, Inc.

Registration Statement on Form S-1, as amended

File No. 333-222990

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), BioXcel Therapeutics, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above (the “Registration Statement”) be accelerated so that it will become effective at 4:00 p.m., Eastern Standard Time, on Wednesday, March 7, 2018, or as soon thereafter as possible.  In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

 

Once the Registration Statement is effective, please orally confirm the event with our counsel, Sheppard, Mullin, Richter & Hampton LLP by calling Stephen A. Cohen at (212) 653-8166. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Sheppard, Mullin, Richter & Hampton LLP, Attention: Stephen A. Cohen, by facsimile to (917) 438-6137.

 

If you have any questions regarding this request, please contact Stephen A. Cohen of Sheppard, Mullin, Richter & Hampton LLP at (212) 653-8166.

 

Very Truly Yours,

 

 

By:

/s/ Vimal Mehta

 

Name:

Vimal Mehta

 

Title:

Chief Executive Officer

 

cc:                                Jeffrey J. Fessler, Sheppard Mullin, Richter & Hampton LLP

Stephen A. Cohen, Sheppard Mullin, Richter & Hampton LLP